Long-Term Invasive Disease–Free Survival Outcomes With Chemotherapy De-Escalation Using an 18F-FDG PET–Based Pathological Complete Response–Adapted Strategy for HER2+ Early Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
Lancet 2024 Apr 03;[EPub Ahead of Print], JM Pérez-García, J Cortés, M Ruiz-Borrego, M Colleoni, A Stradella, B Bermejo, F Dalenc, S Escrivá-de-Romaní, L Calvo Martínez, N Ribelles, F Marmé, A Cortés, C Albacar, G Gebhart, A Prat, K Kerrou, P Schmid, S Braga, S Di Cosimo, M Gion, G Antonarelli, C Popa, E Szostak, D Alcalá-López, P Gener, J Rodríguez-Morató, L Mina, M Sampayo-Cordero, A Llombart-CussacFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.